INmune Bio Inc.

$INMB announced FDA alignment on an integrated Phase 2b/3 registration pathway for #XPro1595 in early #alzheimers. The FDA raised no objection to the development strategy and confirmed CDR-SB as the sole primary endpoint. Full PR: bit.ly/3MG165k #RegulatoryMilestone

As #RareDiseaseMonth comes to a close, #INmuneBio recognizes the millions affected by #raredisease and the ongoing need for innovation. $INMB is advancing novel therapies for high unmet need conditions like #RDEB, a rare genetic disease with systemic impact beyond the skin.

On the @Xtalks Life Science Podcast, $INMB CEO David Moss discusses #INmuneBio’s dominant-negative inhibitor platform targeting chronic inflammation. From #RDEB to #Alzheimers, learn how innate immunity may reshape treatment. Listen on @YouTube: bit.ly/4aqNHWR

February 14-21 is Alzheimer’s & Dementia Care Education Week, highlighting the role of education and innovation in care for those impacted by #Alzheimers. With support from the @alzassociation, $INMB is advancing therapies targeting the underlying drivers of Alzheimer’s disease.

$INMB CEO & Co-Founder David Moss discusses INmune Bio’s precision immune modulation approach in Drug Discovery Online, highlighting the #CORDStrom and #XPro programs targeting harmful inflammation across rare and neurodegenerative diseases. Read more: bit.ly/4rCt7K2

#INmuneBio advances #CORDStrom for #RDEB with a key regulatory milestone. $INMB has submitted its pre-submission package to the UK MHRA to streamline approval and shorten time-to-market. Full PR: bit.ly/4aq1b5d #RareDisease #RegulatoryMilestone #INMB

#WorldCancerDay underscores the need for smarter, more precise approaches to disease. #INmuneBio studies the innate immune system and how restoring immune balance may support new approaches to #cancer and other serious diseases. $INMB #CancerResearch #Biotech

Recessive Dystrophic Epidermolysis Bullosa (#RDEB) is a rare genetic condition causing fragile skin, blisters, & challenges with eating, swallowing, joints, hair, & more. $INMB is advancing research to improve the lives of those affected. Learn more: bit.ly/47aLA7I

Today we’re spotlighting Mark Lowdell, CSO & CMO of #INmuneBio. Serving in this role since 2015, Mark brings decades of leadership in translational #immunotherapy and cell-based medicine. Learn more: bit.ly/4mRR9hk $INMB #EmployeeSpotlight

#INmuneBio issued a shareholder letter reviewing 2025 milestones & outlining 2026 strategic initiatives, highlighting progress with #XPro1595 in early #Alzheimers disease & continued advancement of #CORDStrom in #RDEB. Read more: bit.ly/4bitRPD $INMB #ShareholderUpdate

In a recent Rare Connection podcast, Mark Lowdell, CSO & Co-Founder of $INMB, discusses #CORDStrom, an investigational cell therapy for #RDEB. The conversation highlights clinical progress, the regulatory path ahead, & patient impact. Listen on @Spotify: bit.ly/4qkdma8

CEO David Moss shares his perspective on the #pharma advances that have shaped the industry over the past 30 years in a @pharmasalmanac roundtable, from biologics to advanced antibody engineering. Full roundtable featuring industry leaders: bit.ly/3LnQzen $INMB

Spotlighting Cory Ellspermann, Interim CFO at #INmuneBio. With nearly 30 years of financial leadership, Cory has been instrumental in strengthening $INMB's financial operations since joining in 2019. Proud to highlight his #leadership. Learn more: bit.ly/4mRR9hk

In a new expert discussion from @ClinicalLeader1, researchers call for a shift beyond legacy clinical trial design. David Moss, CEO and co-founder of $INMB, shares why #biology-driven endpoints and enrolling the right patients matter. Full POV: bit.ly/3YvyqhT

$INMB is advancing therapies for RDEB, a #raredisease affecting skin, causing pain, wounds, & systemic issues. Groups like @debraOfAmerica & @EBResearch support the #RDEB community, working toward better treatments and brighter futures. Learn more: bit.ly/4q2oM2Q

#INmune's CEO, David Moss, joins industry leaders in @pharmasalmanac's roundtable on how capital constraints are reshaping M&A and partnerships across pharma and CDMOs. Read the full roundtable: bit.ly/4aI2spW #INMB #PharmaTrends #Biotech

$INMB CEO David Moss spoke with @timsandle of @digitaljournal on late-stage programs targeting immune dysfunction & chronic inflammation. He shares updates on CORDStrom for #epidermolysisbullosa, XPro for #Alzheimers, and upcoming milestones. Read more: bit.ly/4b3b4Ya

Happy Holidays from #INmuneBio! Wishing you a joyful season and a healthy, successful year ahead. #INMB #HappyHolidays

Featuring Tara Lehner, Vice President of Clinical Operations at #INmuneBio. Tara has 22+ years of experience across pharma, biotech, and CROs, and previously managed a $400 million strategic partnership portfolio. Learn more about the $IMNB team: bit.ly/4mRR9hk

#INmuneBio highlights #XPro & its potential to transform care for those affected by #Alzheimers. Hear from $INMB's CEO on the progress following the Phase 2 trial& next steps in a recent #NanoCapPodcast. Full episode: bit.ly/4o3sckk